Merck & Co Inc
NYSE:MRK

Watchlist Manager
Merck & Co Inc Logo
Merck & Co Inc
NYSE:MRK
Watchlist
Price: 99.8201 USD -1.06%
Market Cap: 247.8B USD

MRK's latest stock split occurred on Jun 3, 2021

The company executed a 1048-for-1000 stock split, meaning that for every 1000 shares held, investors received 1048 new shares.

Before the split, MRK traded at 75.87 per share. Afterward, the share price was about 66.0069.

The adjusted shares began trading on Jun 3, 2021. This was MRK's 6th stock split, following the previous one in Feb 17, 1999.

Last Splits:
Jun 3, 2021
1048-for-1000
Feb 17, 1999
2-for-1
May 26, 1992
3-for-1
May 26, 1988
3-for-1
May 27, 1986
2-for-1
Pre-Split Price
64.6539 75.87
Post-Split Price
66.0069
Before
After
Last Splits:
Jun 3, 2021
1048-for-1000
Feb 17, 1999
2-for-1
May 26, 1992
3-for-1
May 26, 1988
3-for-1
May 27, 1986
2-for-1

Merck & Co Inc
Stock Splits History

MRK Stock Splits Timeline
Jun 3, 2021
Jun 3, 2021
Split 1048-for-1000
x1.048
Pre-Split Price
64.6539 75.87
Post-Split Price
66.0069
Before
After
Feb 17, 1999
Feb 17, 1999
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
21.5068
Before
After
May 26, 1992
May 26, 1992
Split 3-for-1
x3
Pre-Split Price
N/A
Post-Split Price
21.5068
Before
After
May 26, 1988
May 26, 1988
Split 3-for-1
x3
Pre-Split Price
N/A
Post-Split Price
21.5068
Before
After
May 27, 1986
May 27, 1986
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
21.5068
Before
After
Jun 1, 1972
Jun 1, 1972
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
21.5068
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Dec 29, 2025
Ise Chemicals Corp
OTC:ICHMF
10-for-1
x10
32.808 32.808 USD N/A
Dec 29, 2025
Bridgestone Corp
OTC:BRDCF
2-for-1
x2
47.5 47.5 USD N/A
Dec 29, 2025
Ibiden Co Ltd
OTC:IBIDF
2-for-1
x2
71.8 71.8 USD N/A
Dec 29, 2025
Itochu Corp
OTC:ITOCF
5-for-1
x5
59.65 59.65 USD N/A
Dec 29, 2025
Sumitomo Realty & Development Co Ltd
OTC:SURDF
2-for-1
x2
47.945 47.945 USD N/A
Load More

Merck & Co Inc
Glance View

Nestled in the heart of the pharmaceutical industry, Merck & Co., Inc. stands as a titan of innovation and healthcare. Established in 1891, the company has grown and evolved, driven by a mission to discover, develop, and provide innovative products and services that save and improve lives around the world. At the core of Merck’s operations is its commitment to research and development (R&D), which serves as the lifeblood of its product pipeline. With billions poured annually into R&D, Merck seeks to uncover new medical breakthroughs that address unmet medical needs across diverse therapeutic areas, such as oncology, vaccines, infectious diseases, and diabetes. This relentless pursuit of scientific advancement is not only a testament to Merck’s commitment to health but also a critical factor in maintaining its competitive edge in a crowded market. Merck's business model is elegantly straightforward yet highly structured. Primarily, the company's revenue streams are powered by the sales of prescription medications and vaccines that emerge from their exhaustive research efforts. Products like Keytruda, a cancer immunotherapy, and Gardasil, a vaccine for human papillomavirus, are standout performers, championing Merck's ability to penetrate high-value markets and secure regulatory approvals across the globe. Beyond the development and sale of pharmaceuticals, Merck generates additional revenue through collaborations and partnerships with other companies, leveraging co-development and marketing agreements to extend its reach. Underpinning Merck's financial model is its rigorous approach to cost management and strategic acquisitions, which bolster its robust product line-up and keep the engines of growth humming. This strategic orchestration ensures that while Merck fulfills its corporate mission, it also aligns with shareholder interests, reflecting a harmonious balance that has supported its storied legacy.

MRK Intrinsic Value
HIDDEN
Show
Back to Top